Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R.
Paulitschke V, et al. Among authors: bileck a.
Mol Cancer Ther. 2015 Mar;14(3):757-68. doi: 10.1158/1535-7163.MCT-14-0701. Epub 2015 Jan 22.
Mol Cancer Ther. 2015.
PMID: 25612618